Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Double figures if the develop compound molecules inhibitors to treat Corona Virus and other Viruses such SARS-CoV-2 and influenza has catalyst positive data results this provides lifetime immunity.
Cocrystal Pharma Inc will be releasing the compound molecules used to develop drug(s) to treat the Corona Virus this month at the end of the year or sooner before or after Christmas, but before New Year's. I hope this time the company will use a professional to read their press release so this stock can soar like many other antiviral stocks. Dr Gary Wilcox Kansas State University Research Foundation will have something great to celebrate after they released the leading compound molecules used to develop the inhibitors to treat the Covid-19 disease.
Cocrystal Pharma Inc (COCP)
1.6801 ? 0.0201 (1.21%)
Volume: 2,634,907 @12/07/20 3:16:30 PM EST
Bid Ask Day's Range
1.68 1.69 1.6 - 1.737
COCP Detailed Quote
Don't listen to shorty, because Cocrystal Pharma stated in the Science Medical Journal in August 2020 the company Will be releasing the leading compound molecules to develop an inhibitor to Stop and treat the infection caused by the disease at the end of the year.
Just like many think the news will be released before the end of December, so do I. These same compounds are used to treat the SAR disease. Dr Gary Wilcox, the Cocrystal Pharma Research team, and Kansas State University Research Foundation are working very hard to get this treatment develop before the year end.
The vaccine are causing major side effects. Cocrystal Pharma is developing a treatment drug to treat the infection caused by the Corona Virus.
Big month for COCP. Cocrystal Pharma will be releasing the lead compound molecules to develop the treatment inhibitor to treat Coid-19 infection caused the Corona Virus. December is at the end of the year. I expect a press release from now until the 4th week in December from Cocrystal Pharma.
COCP $200 otw
the best things take time.
COCP Renaissance Technologies, holds the largest position in Cocrystal Pharma, Inc. (NASDAQ:COCP). Renaissance Technologies has a $3.6 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Coming in second is Point72 Asset Management, managed by Steve Cohen, which holds a $2.7 million position; less than 0.1%% of its 13F portfolio is allocated to the stock. Some other professional money managers that are bullish comprise Hal Mintz's Sabby Capital, John Overdeck and David Siegel's Two Sigma Advisors and . In terms of the portfolio weights assigned to each position Sabby Capital allocated the biggest weight to Cocrystal Pharma, Inc. (NASDAQ:COCP), around 0.37% of its 13F portfolio. Point72 Asset Management is also relatively very bullish on the stock, designating 0.01 percent of its 13F equity portfolio to COCP.
Consequently, specific money managers have been driving this bullishness. Point72 Asset Management, managed by Steve Cohen, established the most valuable position in Cocrystal Pharma, Inc. (NASDAQ:COCP). Point72 Asset Management had $2.7 million invested in the company at the end of the quarter. Hal Mintz's Sabby Capital also initiated a $2.5 million position during the quarter. The only other fund with a new position in the stock is John Overdeck and David Siegel's Two Sigma Advisors.
Immediate Target prices $4.28, and $8!, short term!!... on the long term, it has huge potential!!
-------------------------------------------
Today's stupidity in stock price move is due "shorting" jerks, Cocp will rally back and more!!!
A little squeeze action here. Turn off the super computers and pull the floor out from under the new investors.....or “consolidation” take your pick. If this was just another round of dilution than it will steadily float back down to a buck or less. Anything Dr Frost has his hands on, imo, takes decades to bring to fruition so dont invest anything you need to eat with, this isnt bitcoin or Tesla!
For those wondering about COCP ownership, here is a breakdown, and for Opko, a link at the bottom would serve the needy!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159809586
* * $COCP Video Chart 11-30-2020 * *
Link to Video - click here to watch the technical chart video
Yes, unfortunately the MMs and other criminals control heavily stock price direction!!...
Breakout? Only 53 million shares in the float, how many times are the MM’s going to trade them before the breakout? Are they buying in by regurgitating them 20-30 times? Fake volume if you ask me. Price should be higher that $2.20ish.
Cocp failed its last breakout during the initial phase of Covid-19, but now it regained the moves, this breakout will put Cocp to all time high, along with its parent Opko!...
check out the breakout alert!!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159802189
COCP $200 otw
reminder its happening now!
* * $COCP Video Chart 11-27-2020 * *
Link to Video - click here to watch the technical chart video
$COCP CASH COW, $31.781M Cash Reading DD & Theory NEWS RELEASE 3-AUG-2020 New published study from K-State virologists identifies potential COVID-19 treatment
KANSAS STATE UNIVERSITY
https://www.eurekalert.org/pub_releases/2020-08/ksu-nps080320.php
[-chart]media.eurekalert.org/multimedia_prod/pub/web/239228_web.jpg[/chart]
MANHATTAN, KANSAS -- Yunjeong Kim and Kyeong-Ok "KC" Chang,
virologists in the College of Veterinary Medicine at Kansas State University,
have published a study showing a possible therapeutic
treatment for COVID-19.
Pathogenic coronaviruses are a major threat to global public health,
as shown by severe acute respiratory syndrome coronavirus, or SARS-CoV;
Middle East respiratory syndrome coronavirus, known as MERS-CoV;
and the newly emerged SARS-CoV-2, the virus that causes COVID-19 infection.
The study, "3C-like protease inhibitors block coronavirus replication
in vitro and improve survival in MERS-CoV-infected mice,"
appears in the Aug. 3 issue of the prestigious medical journal Science Translational Medicine.
It reveals how small molecule protease inhibitors show potency against human coronaviruses.
These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication.
"Vaccine developments and treatments are the biggest targets in
COVID-19 research, and treatment is really key,"
said Chang, professor of diagnostic medicine and pathobiology.
"This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target."
The study demonstrates that this series of optimized coronavirus
3CLpro inhibitors blocked replication of the human coronaviruses
MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS.
These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection.
Chang and Kim have been using National Institutes of Health grants
to develop antiviral drugs to treat MERS and human norovirus infections.
Their work extends to other human viruses such as rhinoviruses and SARS-CoV-2.
"The work that this group of collaborators has been doing on
antivirals and inhibitors for SARS and MERS at K-State for a number
of years has been vital to their ability to quickly pivot to emphasize research on SARS-CoV-2 virus and therapeutics,"
said Peter K. Dorhout, vice president for research at K-State.
Co-collaborators on the research include teams lead by Bill Groutas
at Wichita State University,
Stanley Perlman at the University of Iowa and Scott Lovell at the University of Kansas.
"Drs. Groutas,
Perlman and
Lovell brought decades of experience to our research team,"
Chang said.
"We would not have been able to come this far without important collaborations with our colleagues at other institutions."
"Getting things published right now is very important for the scientific community," Kim said. "I think we are adding valuable information to the antiviral field."
###
The new compounds in the publication are exclusively licensed and being developed by Cocrystal Pharma for COVID-19. K-State Innovations Partners handles commercial technology licensing for the university.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy
of news releases posted to EurekAlert! by contributing institutions
or for the use of any information through the EurekAlert system.
$COCP lot of cash, $COCP is cash cow. Reports $31.781M Cash On Hand As Of Sept. 30
*Cocrystal Pharma Q3 Sales $489K, Reports $31.781M Cash On Hand As Of Sept. 30
Benzinga
Traded almost 1 1/2 times the entire float! Cohen only bought what 2.8 million shares, looks like someone took advantage of this news. This is what use to happen in the good ole days when Dr Frost and associates use to buy stock in a company, volume would go through the roof and those in the know would be getting out.
* * $COCP Video Chart 11-25-2020 * *
Link to Video - click here to watch the technical chart video
Perhaps. Volume was very heavy and the PPS didn't spike all that much.
COCP
Might just be they used Cohen for a nice round of dillution. You will see, if so it normally trickles back down to under a buck!
is the Run indicate Vaccine progress!!....along with OPK, COCPs partnership with Merck, could make this tiny company into big time!!!...big competitor for other covid-19 vaccines!!
Nice run. Those that bought my shares are green ... I loaded MORE premarket yesterday, so I'm good.
COCP
Volume is very, very good, today.
How far are we running for ??any target fellas here??
Bought more and sold more. Then realized my gambler switch had flipped. Out for now while all green.
COCP
Holding a little is good...keeps it on your radar screen...stay safe.
Holding a little ... I'm happy also.
COCP
I am out at about 7A and happy.
Will monitor.
Trading nicely pre ... dipping ..
COCP
Premarket up strong.
COCP
* * $COCP Video Chart 11-24-2020 * *
Link to Video - click here to watch the technical chart video
I think folks are waiting for good news.
Stay safe.
AJ
Today was a pretty good pump run on a theoretical guess article. Me thinks when the judge is done with this in December it'll be a different story.
https://ir.cocrystalpharma.com/press-releases/detail/100/cocrystal-pharma-announces-notice-of-pendency-and-proposed
But who knows.
All imo
Congrats on the gain though!!
No.
He is saying Nov is tax loss selling season and stocks that got clobbered recover in Jan...it is called "the January Effect."
So your saying the run is over? One good pop and it's done?
lol my young son found this one as a Jan tax loss trade he has a list of about 20 stocks. I gave him 200k to invest in the Jan effect only. It has worked for me for the past 30 yrs I showed him what to look for and he put together a great list. He bot his first 50k lot under .80 then told me about it.Love the idea of the trade and bot a big chunk for me the other day.To make 68% in 2 days is great and the profits needed to be taken LOL boom the Jan effect didnt even happen here YET but I did take some profit today he wants to hold all his shares till the first week of Jan. I made him sell 20% of his position. My Son has found a winner with COCP and made his daddy some bu cu bucks already.
BIG RATING, $4.50 TARGET !!!!! [To this end, Selvaraju rates COCP a Buy along with a $4.50 price target. Should this target be met, a 417% upside potential could be in store. (To watch Selvaraju’s track record, click here)]
https://finance.yahoo.com/news/billionaire-steven-cohen-pulls-trigger-144600355.html
It is already popping...we will see if it is long-lived...my best guess is institutional nibbling, while trying to keep the PPS down...stay safe.
I haven’t checked in for a while, I think it’s finally time for COCP to pop
Large block trades suggest institutions are nibbling, while trying to avoid PPS spike, and we know news before calendar year end.
Stay safe.
AJ
"Pulling the trigger on COCP for the first time, Point72 purchased more than 2.8 million shares. The value of the firm’s new holding comes in at over $2.5 million."
https://finance.yahoo.com/news/billionaire-steven-cohen-pulls-trigger-144600355.html
CNBC just had a table of the firms with Covid 19 stuff in the pipeline and I did not see Merck listed. Merck is already funding influenza, and is the most likely choice for an additional strategic partnership IMHO. We will see.
COCP big money is in and still adding now the covid-19 news that will rock the world....
I think that is a good strategy.
Stay safe.
AJ
I traded in some I had bought for $. I hold some and trade some at times.
Followers
|
103
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3011
|
Created
|
09/05/13
|
Type
|
Free
|
Moderators |
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses,
influenza viruses, and noroviruses.. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated
in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and
collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company’s molecule for the
treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program
to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.
Our proprietary structural biology, enzymology and medicinal chemistry expertise enable us to develop novel antiviral agents.
These technologies and our market-focused approach to drug discovery are designed to effectively create small molecule therapeutics
that are safe, effective and convenient to administer.
Our technology provides a 3-D structure of inhibitor complexes at near-atomic resolution and immediate insight to guide SAR.
This helps us identify novel binding sites and allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement.
For any given viral disease, there are different subtypes of viruses that cause the disease. For example, there are six different subtypes of virus that cause hepatitis C.
In hepatitis C, these subtypes are termed "genotypes." Each hepatitis C genotype is common in some parts of the world and rare in others.
Our technology allows us to develop drug candidates that are effective against all subtypes of a given virus. The drug candidate is called broad spectrum.
Viral resistance is a major obstacle to developing effective antiviral therapies that target viral molecules. Viruses reproduce rapidly and in enormous quantities.
During reproduction, random variations in viral molecules called mutations spontaneously develop. If such a mutation occurs in a viral molecule that is targeted
by an antiviral therapy that therapy may no longer be effective against the mutated virus. These mutated or "resistant viruses" can freely infect and multiply even
in individuals who have received treatment. In some cases, resistant virus strains may even predominate. For example, in the 2009 swine influenza pandemic,
the predominant strain was resistant to the best available therapies.
To overcome this obstacle, we identify and target critical components of viral replication enzymes that are crucial to the function of the enzyme and sensitive to change.
Any mutation in these critical enzyme components is likely to inactivate the enzyme and, in turn render the virus incapable of replicating. We test the effectiveness of
our compounds against potential viral mutations and select compounds with the highest barrier to resistance.
Patients at risk for suffering from many viral infections have few effective antiviral treatments from which to choose. Furthermore, some available treatment options have characteristics that limit their market potential. They are either priced too high, poorly tolerated, inconvenient to administer, ineffective against some viral subtypes or prone to emergence of resistance.
Our technology is based on the work of our Chief Scientist and Chairman of our Scientific Advisory Board, Dr. Roger Kornberg, and Dr. Raymond Schinazi.
Dr. Kornberg was awarded the 2006 Nobel Prize for Chemistry for his work to visualize a replication enzyme called RNA polymerase in action.
Using techniques called protein cocrystallization and X-ray crystallography, Dr. Kornberg and his colleagues generated three dimensional pictures
similar to the one on the left of RNA being transcribed by an RNA polymerase.
Dr. Schinazi is a world-class expert in discovering novel nucleoside therapeutics. He co-founded several successful antiviral companies including
Triangle Pharmaceuticals Inc., Idenix Pharmaceuticals Inc. and Pharmasset, Inc.
We are leveraging both Dr. Kornberg's and Dr. Schinazi's expertise in these methods to identify and develop new antiviral compounds.
Using these methods, our scientists are able to:
Influenza is a severe respiratory illness caused by either the influenza A or B virus that results in outbreaks of disease mainly during the winter months.
Currently approved antiviral treatments for influenza are partially effective and prone to viral resistance. Strains of flu virus that are resistant to approved treatments,
osteltamivir (Tamiflu™), zanamavir (Relenza™) and Xofluza have appeared and in some cases are predominant.
For example, the predominant strain of the 2009 swine influenza pandemic was resistant to Tamiflu™.
These drugs target one of two viral proteins, hemagglutinin or neuraminidase, neither of which is highly conserved between viral strains.
In fact, different influenza virus strains such as H1N1 and H5N1 are named by their respective differences in hemagglutinin (H) and neuraminidase (N) proteins.
The ability of the influenza virus to produce viable variants of these two proteins is the key to its ability to develop resistance.
To learn more about influenza, please visit the information page at the Center for Disease Control and Prevention (CDC).
References: https://www.cdc.gov/flu/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |